ARCHIVES

Dendritic Cell Vaccine May Boost Median Survival

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

STI-571 Effects Are Lasting Against GI Stromal Tumors

July 26, 2002

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

AACR Using Its Clout To Urge Higher NCI Budget

May 24, 1991

NCI-Approved Clinical Trials

July 30, 2004

Low Prevalence Of Tamoxifen Use For Cancer Prevention

February 26, 2010

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005